OncoMatch/Clinical Trials/NCT05887882
Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors
Is NCT05887882 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells for pediatric brain tumor.
Treatment: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells — This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, or getting worse (progressive). Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings. Giving NK cells from unrelated donors who are screened for optimal cell qualities and determined to be safe and healthy may be effective in treating supratentorial malignant brain tumors in children and young adults.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiation therapy — first-line
participants must have completed first-line treatment with radiation and/or chemotherapy prior to participating in this trial if applicable
Must have received: cytotoxic chemotherapy — first-line
participants must have completed first-line treatment with radiation and/or chemotherapy prior to participating in this trial if applicable
Lab requirements
Blood counts
Peripheral ANC >750/mm^3. Platelet count >75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to registration).
Kidney function
Serum creatinine ≤ 1.5 x ULN based on age/gender.
Liver function
Total bilirubin ≤ 1.5 x ULN for age; in presence of Gilbert's syndrome, total bilirubin ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN. ALT ≤ 3 x ULN. AST ≤ 3 x ULN.
Adequate Bone Marrow Function: Peripheral ANC >750/mm^3; Platelet count >75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to registration). Adequate Renal Function: Serum creatinine ≤ 1.5 x ULN based on age/gender. Adequate Liver Function: Total bilirubin ≤ 1.5 x ULN for age; in presence of Gilbert's syndrome, total bilirubin ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN. ALT ≤ 3 x ULN. AST ≤ 3 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- Children's Hospital Los Angeles · Los Angeles, California
- University of California, San Francisco · San Francisco, California
- Indiana University · Indianapolis, Indiana
- Johns Hopkins · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify